Free Trial

Bingham Private Wealth LLC Takes $240,000 Position in Verona Pharma PLC American Depositary Share $VRNA

Verona Pharma PLC American Depositary Share logo with Medical background

Key Points

  • Bingham Private Wealth LLC acquired a $240,000 stake in Verona Pharma PLC during the second quarter by purchasing 2,536 shares of the company's stock.
  • Insider trading was noted with Director Vikas Sinha selling 4,328 shares at an average price of $13.14, leading to a 4.40% decrease in their ownership.
  • Verona Pharma reported a quarterly earnings beat with $0.13 earnings per share, surpassing the analysts' expectations of ($0.01).
  • Five stocks we like better than Verona Pharma PLC American Depositary Share.

Bingham Private Wealth LLC purchased a new stake in shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 2,536 shares of the company's stock, valued at approximately $240,000.

Other hedge funds have also modified their holdings of the company. Sumitomo Mitsui Trust Group Inc. bought a new stake in shares of Verona Pharma PLC American Depositary Share during the first quarter valued at approximately $284,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Verona Pharma PLC American Depositary Share by 366.0% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,486 shares of the company's stock valued at $720,000 after purchasing an additional 9,021 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Verona Pharma PLC American Depositary Share by 14.0% during the first quarter. GAMMA Investing LLC now owns 1,837 shares of the company's stock valued at $117,000 after purchasing an additional 225 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Verona Pharma PLC American Depositary Share during the second quarter valued at approximately $1,492,000. Finally, Cambridge Investment Research Advisors Inc. grew its stake in shares of Verona Pharma PLC American Depositary Share by 31.3% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 6,168 shares of the company's stock valued at $392,000 after purchasing an additional 1,469 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

Insider Buying and Selling at Verona Pharma PLC American Depositary Share

In related news, Director Vikas Sinha sold 4,328 shares of the firm's stock in a transaction on Friday, August 1st. The shares were sold at an average price of $13.14, for a total transaction of $56,869.92. Following the sale, the director directly owned 94,112 shares in the company, valued at $1,236,631.68. This trade represents a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director David R. Ebsworth sold 1,904 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $13.14, for a total transaction of $25,018.56. Following the sale, the director owned 880,499 shares in the company, valued at approximately $11,569,756.86. The trade was a 0.22% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 540,584 shares of company stock valued at $7,103,274 over the last quarter. 4.80% of the stock is currently owned by corporate insiders.

Verona Pharma PLC American Depositary Share Trading Up 0.1%

Shares of NASDAQ VRNA opened at $106.91 on Tuesday. The company's fifty day moving average is $105.95 and its 200-day moving average is $88.27. The stock has a market cap of $9.21 billion, a price-to-earnings ratio of -107.99 and a beta of 0.05. Verona Pharma PLC American Depositary Share has a twelve month low of $31.09 and a twelve month high of $106.93. The company has a quick ratio of 10.54, a current ratio of 10.71 and a debt-to-equity ratio of 0.87.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported $0.13 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.14. The company had revenue of $103.14 million for the quarter, compared to analysts' expectations of $90.41 million. Verona Pharma PLC American Depositary Share had a negative net margin of 36.62% and a negative return on equity of 21.12%. Equities research analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VRNA shares. TD Cowen cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Wolfe Research cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Truist Financial cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, July 9th. Piper Sandler cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 10th. Finally, Wells Fargo & Company cut shares of Verona Pharma PLC American Depositary Share from a "strong-buy" rating to a "hold" rating and reduced their price objective for the company from $138.00 to $107.00 in a research note on Thursday, July 10th. Two analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus target price of $109.00.

Check Out Our Latest Research Report on VRNA

Verona Pharma PLC American Depositary Share Company Profile

(Free Report)

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.

Read More

Institutional Ownership by Quarter for Verona Pharma PLC American Depositary Share (NASDAQ:VRNA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Verona Pharma PLC American Depositary Share Right Now?

Before you consider Verona Pharma PLC American Depositary Share, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma PLC American Depositary Share wasn't on the list.

While Verona Pharma PLC American Depositary Share currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report
Like this article? Share it with a colleague.